Citation

Carminati GG, Deriaz N, Bertschy G. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30(2): 312-315.

Affiliation

Division of adult psychiatry, Department of psychiatry, Psychiatry of Mental Development Unit, University hospitals of Geneva. Giuliana.GalliCarminati@hcuge.ch

Copyright

(Copyright © 2006, Elsevier Publishing)

DOI

10.1016/j.pnpbp.2005.10.002

PMID

16307837

Abstract

In our clinical practice, we have had good experiences with venlafaxine in the treatment of self-injurious behavior (SIB) and attention deficit/hyperactivity disorders (ADHD)-like symptoms in patients with pervasive developmental disorders (PDD), and we report here three cases of possible therapeutic response: (A) a 17-year-old boy with autism and severe behavioral symptoms, including aggression toward self or property, SIB and hyperactivity, who appeared to respond to low-dose venlafaxine (18.75 mg/day); (B) a 23-year-old woman with autism hyperactivity who appeared to respond to low-dose venlafaxine (18.75 mg/day); (C) a 17-year-old girl with autism hyperactivity who appeared to respond to low-dose venlafaxine (18.75 mg/day). Follow-ups occurred respectively 18, 36 and 6 months after treatment initiation, making it possible to observe the stability of the clinical improvement in these cases.

Language: en